EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Naoxueshu Oral Liquid Accelerates Post-Craniotomy Hematoma Absorption in Patients: An Open-Label, Multicenter, and Randomized Controlled Trial

Qiu He, Fu-Xin Lin, Jin-Ye Su, Ling-Yun Zhuo, Qing Zhu, Xiao-Chuan Sun, Rong-Cai Jiang, Zhi-Gang Yao, Lei Wang, Yan-Wei Dang, De-Zhong Liu, Yang Liu und 6 weitere

Chinese Journal of Integrative Medicine · 2024

DOI: 10.1007/s11655-024-3902-6 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Chinese Journal of Integrative Medicine, 2024. Verfasst von Qiu He und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Neurosurgery Research Institute, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350004, China. Hauptthemen laut MEDLINE: Craniotomy, Drugs, Chinese Herbal, Hematoma. Die Arbeit nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To investigate whether Naoxueshu Oral Liquid (NXS) could promote hematoma absorption in post-craniotomy hematoma (PCH) patients. METHODS: This is an open-label, multicenter, and randomized controlled trial conducted at 9 hospitals in China. Patients aged 18-80 years with post-craniotomy supratentorial hematoma volume ranging from 10 to 30 mL or post-craniotomy infratentorial hematoma volume less than 10 mL, or intraventricular hemorrhage following cranial surgery were enrolled. They were randomly assigned at a 1:1 ratio to the NXS (10 mL thrice daily for 15 days) or control groups using a randomization code table. Standard medical care was administered in both groups. The primary outcome was the percentage reduction in hematoma volume from day 1 to day 15. The secondary outcomes included the percentage reduction in hematoma volume from day 1 to day 7, the absolute reduction in hematoma volume from day 1 to day 7 and 15, and the change in neurological function from day 1 to day 7 and 15. The safety was closely monitored throughout the study. Moreover, subgroup analysis was performed based on age, gender, history of diabetes, and etiology of intracerebral hemorrhage (ICH). RESULTS: A total of 120 patients were enrolled and randomly assigned between March 30, 2018 and April 15, 2020. One patient was lost to follow-up in the control group. Finally, there were 119 patients (60 in the NXS group and 59 in the control group) included in the analysis. In the full analysis set (FAS) analysis, the NXS group had a greater percentage reduction in hematoma volume from day 1 to day 15 than the control group [median (Q1, Q3): 85% (71%, 97%) vs. 76% (53%, 93%), P 0.05). Furthermore, no adverse events were reported during the study. In the FAS analysis, the NXS group exhibited a higher percentage reduction in hematoma volume on day 15 in the following subgroups: male patients, patients younger than 65 years, patients without diabetes, or those with initial cranial surgery due to ICH (all P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CraniotomyDrugs, Chinese HerbalHematomaAdolescentAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedYoung AdultAdministration, Oral

Stichwörter der Autor:innen

Chinese medicineNaoxueshu Oral Liquidhematoma absorptionpost-craniotomy hematomarandomized controlled trial

Substanzen

Drugs, Chinese Herbal

Autor:innen und Institutionen

  • Department of Neurosurgery, Neurosurgery Research Institute, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350004, China.
  • Department of Neurosurgery, Binhai Branch of National Regional Medical Center, The First Affiliated Hospital, Fujian Medical University, Fuzhou, 350209, China.
  • Clinical Research and Translation Center, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350004, China.
  • Fujian Clinical Research Center for Neurological Diseases, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350004, China.
  • Fujian Provincial Institutes of Brain Disorders and Brain Sciences, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350004, China.
  • Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, 215000, China.

Zitieren

APA

He, Q., Lin, F. X., Su, J. Y., Zhuo, L. Y., Zhu, Q., Sun, X. C., Jiang, R. C., Yao, Z. G., Wang, L., Dang, Y. W., Liu, D. Z., Liu, Y., Fang, W. H., Wang, F. Y., Lin, Y. X., Wang, A. X., Wang, D. L., & Kang, D. Z. (2024). Naoxueshu Oral Liquid Accelerates Post-Craniotomy Hematoma Absorption in Patients: An Open-Label, Multicenter, and Randomized Controlled Trial. Chinese Journal of Integrative Medicine. https://doi.org/10.1007/s11655-024-3902-6

Vancouver

He Q, Lin FX, Su JY, Zhuo LY, Zhu Q, Sun XC, et al. Naoxueshu Oral Liquid Accelerates Post-Craniotomy Hematoma Absorption in Patients: An Open-Label, Multicenter, and Randomized Controlled Trial. Chinese Journal of Integrative Medicine. 2024. doi:10.1007/s11655-024-3902-6

BibTeX
@article{He2024,
  author = {He, Qiu and Lin, Fu-Xin and Su, Jin-Ye and Zhuo, Ling-Yun and Zhu, Qing and Sun, Xiao-Chuan and Jiang, Rong-Cai and Yao, Zhi-Gang and Wang, Lei and Dang, Yan-Wei and Liu, De-Zhong and Liu, Yang and Fang, Wen-Hua and Wang, Fang-Yu and Lin, Yuan-Xiang and Wang, An-Xin and Wang, Deng-Liang and Kang, De-Zhi},
  title = {Naoxueshu Oral Liquid Accelerates Post-Craniotomy Hematoma Absorption in Patients: An Open-Label, Multicenter, and Randomized Controlled Trial},
  journal = {Chinese Journal of Integrative Medicine},
  year = {2024},
  doi = {10.1007/s11655-024-3902-6}
}
Kostenlos starten →